Cargando…

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary. We designed a clinical trial to investigate two hypotheses: i) higher doses of venetoclax ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gutman, Jonathan A., Winters, Amanda, Kent, Andrew, Amaya, Maria, McMahon, Christine, Smith, Clayton, Jordan, Craig T., Stevens, Brett, Minhajuddin, Mohammad, Pei, Shanshan, Schowinsky, Jeffrey, Tobin, Jennifer, O’Brien, Kelly, Falco, Angela, Taylor, Elizabeth, Brecl, Constance, Zhou, Katie, Ho, Phuong, Sohalski, Connor, Dell-Martin, Jessica, Ondracek, Olivia, Abbott, Diana, Pollyea, Daniel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Article - Acute Myeloid Leukemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542846/ https://www.ncbi.nlm.nih.gov/pubmed/37051756 http://dx.doi.org/10.3324/haematol.2023.282681

Ejemplares similares

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
por: Pabst, Thomas, et al.
Publicado: (2023)

AML-168: The Assessment of COVID-19 Evolution in Patients with Oncological Diseases Admitted in an Intensive Care Unit of One Romanian Center
por: Popov, Viola Maria, et al.
Publicado: (2021)

AML-145: Outcomes of Induction Therapy in Patients with Acute Myeloid Leukemia During Covid-19 Pandemic: A Retrospective Study from a Tertiary Care Cancer Centre
por: Iqbal, Asif, et al.
Publicado: (2021)

AML-355: Incidence and Severity of COVID-19 among Inpatients with Hematologic Malignancies
por: Wozniaki, Natalia, et al.
Publicado: (2021)

AML-075: Converting In-Person Research Procedures to a Virtual Platform During the COVID-19 Pandemic in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Tinsley, Sara, et al.
Publicado: (2021)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

A risk score based on real-world data to predict early death in acute promyelocytic leukemia
por: Österroos, Albin, et al.
Publicado: (2022)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements
por: Grasedieck, Sarah, et al.
Publicado: (2021)

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy
por: Ihlow, Jana, et al.
Publicado: (2021)

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
por: Arruda, Lucas C. M., et al.
Publicado: (2022)

A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia
por: Xu, Xi, et al.
Publicado: (2022)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc
por: Garcia-Cuellar, Maria-Paz, et al.
Publicado: (2022)

Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia
por: Tuval, Amos, et al.
Publicado: (2022)

Persistent DNA damage and oncogenic stress-induced Trem1 promotes leukemia in mice
por: Li, Xue, et al.
Publicado: (2022)

Interplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor-α with the PML/RAR α fusion protein on super-enhancers
por: Wu, Shishuang, et al.
Publicado: (2022)

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias
por: Paolillo, Rosa, et al.
Publicado: (2022)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
por: Kayser, Sabine, et al.
Publicado: (2022)

Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia
por: Sourdeau, Elise, et al.
Publicado: (2022)

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
por: Marchesi, Francesco, et al.
Publicado: (2022)

Analysis of rare driving events in pediatric acute myeloid leukemia
por: Noort, Sanne, et al.
Publicado: (2022)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
por: Nilsson, Christer, et al.
Publicado: (2022)

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
por: Sahoo, Binay K., et al.
Publicado: (2022)

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
por: Jia, Yannan, et al.
Publicado: (2023)

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2023)

Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity
por: O’Brien, Cristiana, et al.
Publicado: (2023)

Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency
por: Rein, Avigail, et al.
Publicado: (2022)

Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine
por: Assouline, Sarit, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cdve3pd8tjsuctf28pklcmnf0t